JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma

(MedPage Today) -- Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings from a single-arm phase II study showed. Among...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news